Development and Preclinical Characterization of a Solid Oral Formulation of a Synthetic Biotic Medicine for the Treatment of PKU

Blood Ammonia Levels are Labile and Responsive to Protein Intake in Patients with Compensated Cirrhosis without Overt Hepatic Encephalopathy 1.7 MB

Slides from Synlogic Investor and Analyst Presentation at SITC 2018 5.6 MB

Development of a STING Agonist-producing Synthetic Biotic™ Medicine to Activate Innate and Adaptive Immunity and Drive Antitumor Immune Responses 5.1 MB

7 MB

A Synthetic Biology Approach for the Treatment of Cancer and Inflammation, 3.9 MB

An Engineered E. coli Nissle for the treatment of Phenylketonuria (PKU) 2 MB

3.8 MB

Activation of innate and adaptive immunity via combinatorial immunotherapy using Synthetic Biotic™ Medicines 4 MB

Tolerability and Kinetics of SYNB1020 in a Phase 1, First-in-human, Healthy Adult Volunteer Study 3.9 MB